Importance The US is currently an epicenter of the coronavirus disease 2019 (COVID-19)
pandemic, yet few national data are available on patient characteristics, treatment, and …

Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has
emerged as an important toxicity among patients with cancer. Methods We collected data on …

Rationale & Objective Cytokine release syndrome is a well-known complication of chimeric
antigen receptor T-cell (CAR-T) therapy and can lead to multiorgan dysfunction. However …

Background Programmed cell death receptor ligand 1 (PD-L1) inhibitors are immune
checkpoint inhibitors (ICIs) with a side effect profile that may differ from other classes of ICIs …

Introduction Acute kidney injury (AKI) is a common complication in patients with severe
COVID-19. We sought to compare the AKI incidence and outcomes among patients …

Authors' Contributions: research idea and study design: MES, KLR, TGN data acquisition:
DFC, IAS, HS, ML, LZ; data analysis/interpretation: DFC, SG, DEL, OR, ZDD, TGN, LZ, KLR …

Results A total of 18 patients with eGFR< 30 ml/min per 1.73 m 2 at the time of remdesivir
initiation were included; baseline characteristics are shown in Table 1. The median age was …

Background Remdesivir is not currently approved for patients with eGFR< 30 ml/min per
1.73 m 2. We aimed to determine the safety of remdesivir in patients with kidney failure …

Immune checkpoint inhibitors (ICIs) offer potential life-saving benefits to patients with cancer
but can cause multisystem immune-related adverse events (irAEs) that, when severe, may …

Background Chronic kidney disease (CKD) is an important risk factor for mortality from
COVID-19. Remdesivir has been shown to shorten time to recovery in patients with severe …